MET is altered in 5.01% of non-small cell lung carcinoma patients [4].

MET Overexpression is an inclusion criterion in 17 clinical trials for non-small cell lung carcinoma, of which 10 are open and 7 are closed. Of the trials that contain MET Overexpression and non-small cell lung carcinoma as inclusion criteria, 6 are phase 1 (3 open), 4 are phase 1/phase 2 (3 open), 5 are phase 2 (3 open), and 2 are phase 3 (1 open) [5].

MET is altered in 2.83% of malignant solid tumor patients [4].

MET Overexpression is an inclusion criterion in 15 clinical trials for malignant solid tumor, of which 5 are open and 10 are closed. Of the trials that contain MET Overexpression and malignant solid tumor as inclusion criteria, 9 are phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 4 are phase 2 (3 open) [5].

MET is altered in 2.59% of hepatocellular carcinoma patients [4].

MET Overexpression is an inclusion criterion in 6 clinical trials for hepatocellular carcinoma, of which 5 are open and 1 is closed. Of the trials that contain MET Overexpression and hepatocellular carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1 (2 open), 2 are phase 2 (2 open), and 1 is phase 3 (0 open) [5].

MET is altered in 1.14% of breast carcinoma patients [4].

MET Overexpression is an inclusion criterion in 4 clinical trials for breast carcinoma, of which 1 is open and 3 are closed. Of the trials that contain MET Overexpression and breast carcinoma as inclusion criteria, 1 is early phase 1 (0 open), 2 are phase 1 (1 open), and 1 is phase 1/phase 2 (0 open) [5].

MET is altered in 2.69% of cancer patients [4].

MET Overexpression is an inclusion criterion in 4 clinical trials for cancer, of which 2 are open and 2 are closed. Of the trials that contain MET Overexpression and cancer as inclusion criteria, 1 is early phase 1 (0 open) and 3 are phase 1 (2 open) [5].

MET is altered in 2.14% of colorectal carcinoma patients [4].

MET Overexpression is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 1 is open and 2 are closed. Of the trials that contain MET Overexpression and colorectal carcinoma as inclusion criteria, 3 are phase 1 (1 open) [5].

MET is altered in 1.29% of prostate carcinoma patients [4].

MET Overexpression is an inclusion criterion in 3 clinical trials for prostate carcinoma, of which 3 are open and 0 are closed. Of the trials that contain MET Overexpression and prostate carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [5].

MET is altered in 4.29% of adenocarcinoma of the gastroesophageal junction patients [4].

MET Overexpression is an inclusion criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 0 are open and 2 are closed. Of the trials that contain MET Overexpression and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (0 open) [5].

MET is altered in 4.83% of endometrial carcinoma patients [4].

MET Overexpression is an inclusion criterion in 2 clinical trials for endometrial carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET Overexpression and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

MET is altered in 3.56% of gastric adenocarcinoma patients [4].

MET Overexpression is an inclusion criterion in 2 clinical trials for gastric adenocarcinoma, of which 0 are open and 2 are closed. Of the trials that contain MET Overexpression and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (0 open) [5].

MET is altered in 3.53% of gastric carcinoma patients [4].

MET Overexpression is an inclusion criterion in 2 clinical trials for gastric carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET Overexpression and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open) [5].

MET is altered in 6.7% of melanoma patients [4].

MET Overexpression is an inclusion criterion in 2 clinical trials for melanoma, of which 1 is open and 1 is closed. Of the trials that contain MET Overexpression and melanoma as inclusion criteria, 1 is early phase 1 (0 open) and 1 is phase 1 (1 open) [5].

MET is altered in 0.9% of pancreatic adenocarcinoma patients [4].

MET Overexpression is an inclusion criterion in 2 clinical trials for pancreatic adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET Overexpression and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [5].

MET is altered in 3.94% of renal cell carcinoma patients [4].

MET Overexpression is an inclusion criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MET Overexpression and renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

MET is altered in 3.25% of squamous cell lung carcinoma patients [4].

MET Overexpression is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MET Overexpression and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is no phase specified (1 open) [5].

MET is altered in 2.83% of urothelial carcinoma patients [4].

MET Overexpression is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET Overexpression and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [5].

MET is altered in 0.6% of adrenal cortex carcinoma patients [4].

MET Overexpression is an inclusion criterion in 1 clinical trial for adrenal cortex carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Overexpression and adrenal cortex carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET Overexpression is an inclusion criterion in 1 clinical trial for alveolar soft part sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET Overexpression and alveolar soft part sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET is altered in 0.95% of B-cell non-hodgkin lymphoma patients [4].

MET Overexpression is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MET Overexpression and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET is altered in 2.77% of bladder carcinoma patients [4].

MET Overexpression is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Overexpression and bladder carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MET is altered in 2.26% of cervical squamous cell carcinoma patients [4].

MET Overexpression is an inclusion criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Overexpression and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MET is altered in 1.7% of cholangiocarcinoma patients [4].

MET Overexpression is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Overexpression and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET Overexpression is an inclusion criterion in 1 clinical trial for clear cell sarcoma of soft tissue, of which 1 is open and 0 are closed. Of the trial that contains MET Overexpression and clear cell sarcoma of soft tissue as inclusion criteria, 1 is phase 2 (1 open) [5].

MET is altered in 2.14% of colorectal adenocarcinoma patients [4].

MET Overexpression is an inclusion criterion in 1 clinical trial for colorectal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains MET Overexpression and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

MET is altered in 4.15% of esophageal carcinoma patients [4].

MET Overexpression is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MET Overexpression and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

MET is altered in 1.03% of Ewing sarcoma patients [4].

MET Overexpression is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET Overexpression and Ewing sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET is altered in 4.12% of glioblastoma patients [4].

MET Overexpression is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains MET Overexpression and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MET is altered in 1.49% of gliosarcoma patients [4].

MET Overexpression is an inclusion criterion in 1 clinical trial for gliosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET Overexpression and gliosarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MET is altered in 2.08% of head and neck carcinoma patients [4].

MET Overexpression is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Overexpression and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MET is altered in 2.75% of head and neck squamous cell carcinoma patients [4].

MET Overexpression is an inclusion criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MET Overexpression and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MET Overexpression is an inclusion criterion in 1 clinical trial for hepatoblastoma, of which 1 is open and 0 are closed. Of the trial that contains MET Overexpression and hepatoblastoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET is altered in 1.61% of high grade ovarian serous adenocarcinoma patients [4].

MET Overexpression is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Overexpression and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MET is altered in 1.36% of lymphoma patients [4].

MET Overexpression is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MET Overexpression and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MET is altered in 0.99% of mesothelioma patients [4].

MET Overexpression is an inclusion criterion in 1 clinical trial for mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains MET Overexpression and mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].

MET is altered in 0.93% of multiple myeloma patients [4].

MET Overexpression is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains MET Overexpression and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET is altered in 0.69% of osteosarcoma patients [4].

MET Overexpression is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET Overexpression and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET is altered in 16.9% of papillary renal cell carcinoma patients [4].

MET Overexpression is an inclusion criterion in 1 clinical trial for papillary renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Overexpression and papillary renal cell carcinoma as inclusion criteria, 1 is phase 3 (1 open) [5].

MET is altered in 2.46% of rhabdomyosarcoma patients [4].

MET Overexpression is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET Overexpression and rhabdomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET is altered in 1.87% of small intestinal adenocarcinoma patients [4].

MET Overexpression is an inclusion criterion in 1 clinical trial for small intestinal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains MET Overexpression and small intestinal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

MET is altered in 1.48% of soft tissue sarcoma patients [4].

MET Overexpression is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET Overexpression and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET is altered in 0.63% of thyroid gland medullary carcinoma patients [4].

MET Overexpression is an inclusion criterion in 1 clinical trial for thyroid gland medullary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET Overexpression and thyroid gland medullary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MET Overexpression is an inclusion criterion in 1 clinical trial for Wilms tumor, of which 1 is open and 0 are closed. Of the trial that contains MET Overexpression and Wilms tumor as inclusion criteria, 1 is phase 2 (1 open) [5].